COVID-19 Employee Screening Survey Before Work


Survey for Symptomatic Employees Requesting Drive-Thru Testing

 

Breaking News

Evusheld no longer authorized for emergency use in the U.S.

The FDA announced today that tixagevimab-cilgavimab is no longer authorized for emergency use in the U.S. The revised EUA limits Evusheld’s use when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this, Evusheld is not currently authorized for use in the U.S. until further notice. Please see the full press release linked here: https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us. Read more…

Community transmission level in Kentucky

This update taken today from the CDC Tracker for community transmission describes the amount of COVID-19 spread within each county. Health care facilities use Transmission Levels to determine infection control interventions.

COVID-19 community transmission levels in Kentucky

NOTE: Current 7-days is Thu Jan 12 2023 – Wed Jan 18 2023 for case rate and Tue Jan 10 2023 – Mon Jan 16 2023 for percent positivity. The percent change in counties at each level of transmission is the absolute change compared to the previous 7-day period.

UK researchers find vaccination protects mother and baby from COVID-19

In an article published on UKNow January 11, we learned UK researchers have found that maternal vaccination against COVID-19 works to protect both the mother and baby.

The study was funded by a National Institutes of Health grant and published in the American Journal of Obstetrics and Gynecology Maternal-Fetal Medicine.

 

Community transmission level in Kentucky

This update taken today from the CDC Tracker for community transmission describes the amount of COVID-19 spread within each county. Health care facilities use Transmission Levels to determine infection control interventions.

Map showing COVID community transmission level in Kentucky

NOTE: Current 7-days is Thu Dec 29 2022 – Wed Jan 04 2023 for case rate and Tue Dec 27 2022 – Mon Jan 02 2023 for percent positivity. The percent change in counties at each level of transmission is the absolute change compared to the previous 7-day period.

 

Community transmission level in Kentucky

This update taken from the CDC Tracker for community transmission describes the amount of COVID-19 spread within each county. Health care facilities use Transmission Levels to determine infection control interventions.

COVID Community Transmission Level in Kentucky

NOTE: Current 7-days is Thu Dec 15 2022 – Wed Dec 21 2022 for case rate and Tue Dec 13 2022 – Mon Dec 19 2022 for percent positivity. The percent change in counties at each level of transmission is the absolute change compared to the previous 7-day period.

 

Community transmission level in Kentucky

This update taken from the CDC Tracker for community transmission describes the amount of COVID-19 spread within each county. Health care facilities use Transmission Levels to determine infection control interventions.

Level of COVID transmission in Kentucky

NOTE: Current 7-days is Thu Dec 01 2022 – Wed Dec 07 2022 for case rate and Tue Nov 29 2022 – Mon Dec 05 2022 for percent positivity. The percent change in counties at each level of transmission is the absolute change compared to the previous 7-day period.

 

CDC expands use of updated vaccine for children 6 mos. – 5 yrs.

Following FDA action, on Dec. 9 the CDC expanded use of updated (bivalent) COVID-19 vaccines for children ages 6 months through 5 years.

  • Children ages 6 months through 5 years who previously completed a Moderna primary series are eligible to receive a Moderna bivalent booster 2 months after their final primary series dose.
  • Children ages 6 months through 4 years who are currently completing a Pfizer primary series will receive a Pfizer bivalent vaccine as their third primary dose.

Read more on the CDC site.

Return to work instructions simplified

While our guidance regarding return to work after COVID exposure has not changed, we have simplified the grid to show only the instructions for the “contingency” phase we are in. We hope this will reduce confusion about which guidelines apply.

The full guidelines are here:

 

Updated pharmacotherapy guidance

The FDA announced November 30 that bebtelovimab is no longer authorized for emergency use in the U.S. because it is not expected to neutralize omicron subvariants BQ.1 and BQ.1.1., which based on CDC Nowcast data is above 50% in most regions of the country with a sustained trend of increasing prevalence across all regions (https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region).

Bebtelovimab was previously offered within the UK HealthCare enterprise for outpatient pediatric patients with mild-to-moderate disease and adult inpatients with mild-to-moderate disease admitted for reasons other than COVID-19.

There are alternatives to bebtelovimab to treat mild-to-moderate COVID-19, including nirmatrelvir-ritonavir, remdesivir, and molnupiravir. Use of these agents is outlined in our guidance documents.  Read more…

View All Breaking News